MDPI AG
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Cardiovascular (CV) disease, chronic kidney disease, obesity, and diabetes mellitus have reached epidemic proportions over the past few decades. Accumulating evidence highlights the strong interconnection between these conditions, leading to the definition of a broader disease entity known as cardio-renal-metabolic (CRM) syndrome. This newly recognized clinical entity presents important challenges in identifying the optimal treatment strategy within a holistic, patient-centered framework. In line...
Preuzmite dokument
2025
Paschalis Karakasis
,
Efstratios Karagiannidis
,
Antonios P. Antoniadis
,
Nikolaos Fragakis
,
Athina Nasoufidou
,
Aleksandra Klisic
,
Konstantinos Grigoriou
,
Djordje S. Popovic
,
Panagiotis Stachteas
,
Dimitrios Patoulias
,
Barbara Fyntanidou
... Pogledajte sve
Wiley
Sodium‐glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta‐analysis
AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR‐CM) commonly leads to heart failure but has traditionally been an exclusion criterion in randomized clinical trials (RCTs) of sodium‐glucose cotransporter 2 inhibitors (SGLT2i); therefore, the effects of these drugs in this population remain undocumented. In light of recent studies, this meta‐analysis aimed to investigate the effect of SGLT2i on the prognosis of patients with ATTR‐CM.MethodsA comprehensive search of Medline, Scopus, and...
Preuzmite dokument
2025
Paschalis Karakasis
,
Panagiotis Theofilis
,
Manfredi Rizzo
,
Nikolaos Fragakis
,
Panayotis K Vlachakis
,
Aleksandra Klisic
,
Dimitrios Patoulias
,
Art Schuermans
Bentham Science Publishers Ltd.
Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence
:
Atherosclerotic Cardiovascular Disease (ASCVD) is still one of the leading causes of death globally,
with Coronary Artery Disease (CAD) being the most prevalent form of ASCVD. Patients with type 2 Diabetes
Mellitus (DM) experience an increased risk for ASCVD during the disease course, with CAD being the
most common cause of death among affected individuals, resulting in shorter life expectancy and increased
morbidity among survivors. Recently, 2 novel classes of anti-diabetic drugs, namely Sodium-Glucose...
Preuzmite dokument
2024
Paschalis Karakasis
,
Manfredi Rizzo
,
Nikolaos Fragakis
,
Theocharis Koufakis
,
Michael Doumas
,
Aleksandra Klisic
,
Dimitrios Patoulias
,
George Kassimis
Wiley
Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
AbstractAimsTo conduct a meta‐analysis of randomized controlled trials (RCTs) to evaluate the effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics as an adjunct to insulin therapy in adults with type 1 diabetes mellitus (T1D).MethodsA systematic literature search was conducted through Medline (via PubMed), Cochrane Library, and Google Scholar up to 27 May 2024. Dual‐independent study selection, data extraction,...
Preuzmite dokument
2024
Paschalis Karakasis
,
Fotios Barkas
,
Theocharis Koufakis
,
Michael Doumas
,
Nikolaos Papanas
,
Aleksandra Klisic
,
Djordje S. Popovic
,
Milena Mitrovic
,
Dimitrios Patoulias
